How Does Diversity Affect Innovation in Pharma?
(September 14, 2022)
Studies suggest that a diverse and inclusive workforce augments innovation throughout the pharmaceutical industry. A panel of four leaders discussed their perspectives on these data and how diversity has impacted discoveries within their field. Their formal remarks were followed by an open discussion of questions submitted by seminar registrants and attendees.
Marie A. Bernard, M.D.
Marie A. Bernard, M.D., Chief Officer for Scientific Workforce Diversity (COSWD), NIH
Aida Habtezion, M.D., MSc, FRCPC, AGAF
Aida Habtezion, M.D., MSc, FRCPC, AGAF, Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Graham Jones, Ph.D., D.Sc.
Graham Jones, Ph.D., D.Sc., Head of Connected Health Research and Innovation, Novartis
Michelle McMurry-Heath, M.D., Ph.D.
Michelle McMurry-Heath, M.D., Ph.D., President and CEO, Biotechnology Innovation Organization
Meena Subramanyam, Ph.D.
Meena Subramanyam, Ph.D., Global Program Leader and Conditional T cell Engager Platform Lead, Takeda Oncology
Faith Harrow Plante, Ph.D.
Faith Harrow Plante, Ph.D., Chair of the NIH Training Directors Committee, Scientific Training Director, National Human Genome Research Institute, NIH
Sharon Milgram, Ph.D.
Sharon Milgram, Ph.D., Director of the Office of Intramural Training & Education, NIH